Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Antibody therapies are a type of biologic. They are typically monoclonal antibodies selected to bind to a particular protein (often a cell-surface protein), and produced using recombinant DNA technology.
Cryo-electron microscopy was used to determine the high-resolution structure of the antigen-binding fragment of tusamitamab bound to the A3-B3 domains of CEACAM5. The conformational constraints discovered in this study may inform the rational design of new CEACAM5-targeting therapies.
Engineered protein therapeutics, including antibodies, are valuable drugs offering major health benefits, but they can elicit unwanted immune responses. This Review identifies key challenges in assessing and mitigating the risk of immunogenicity, particularly the generation of anti-drug antibodies, and suggests pragmatic steps to address them.
Selective protein degradation in disease-relevant cells or tissues has seen limited success. Hence, the authors develop Folate Receptor Targeting Chimeras (FRTACs) to specifically target proteins in cancer cells, aiming to reduce on-target, off-tumor toxicity.
The bispecific T cell engager (BiTE) blinatumomab showed promising clinical efficacy in a pilot study of six patients with multidrug-resistant rheumatoid arthritis.
